|Description||BMS-187071 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.|
|Synonyms||BMS 187071; BMS187071; BMS187071; (3-((3-((2,3,3-Trimethyl-2(S)-2-hydroxy-1-oxobutyl)amino)-2-hydroxy-4-phenylbutyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid, 1,1-dimethylethyl ester; [3-[[3-[(2,3,3-Trimethyl-2(S)-2-hydroxy-1-oxobutyl)amino]-2-hydroxy-4|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
The hydrochloride salt form of MK-8718 which has been found to be a HIV protease inhibitor and could be studied in HIV research.
DPC-681, sulfonamide derivatives, is an extremely potent and selective inhibitor of HIV protease. IC90s: wild-type HIV-1=4-40 nM
BMS-186318 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.
A potent inhibitor of HIV-l protease (IC50= 1 nM)
CI-1029 is a nonpeptidic inhibitor of HIV protease, potenat against mutant HIV protease and resistant HIV strains.
MK-8718 has been found to be a HIV protease inhibitor and could be studied in HIV research.
CGP-75355 is an HIV Protease inhibitor (EC50= 0.7 nM).
BMS-187071 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.